Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open Label, Phase II Clinical Trial of Inotuzumab Ozogamicin as Prophylaxis for Relapse in Patients With High-risk Acute B-cell Precursor Acute Lymphoblastic Leukaemia After Allogeneic Stem Cell Haemotopoietic Transplantation

NCT07862946 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT07862946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07862946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open Label, Phase II Clinical Trial of Inotuzumab Ozogamicin as Prophylaxis for Relapse in Patients With High-risk Acute B-cell Precursor Acute Lymphoblastic Leukaemia After Allogeneic Stem Cell Haemotopoietic Transplantation
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
October 30, 2030
Enrollment
30 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphobkastic leukemia, adult